-
Company Insights
New![]()
Innovation and Patenting activity of BioArctic AB Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of BioArctic AB Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be delivered...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – IPH-5201 in Solid Tumor
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.IPH-5201 in Solid Tumor Drug Details: IPH-5201 (OREG-103) is under development for the treatment of solid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Exidavnemab in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Exidavnemab in Parkinson's Disease Drug Details:Exidavnemab (BAN-0805) is under development for the treatment of Parkinson's disease....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Siremadlin Succinate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Siremadlin Succinate in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) Drug Details: Siremadlin succinate (HDM-201) is under...
-
Product Insights
![]()
Neurosurgical Products Pipeline by Stages of Development, Segments, Region, Regulatory Path and Key Companies
Neurosurgical Products Pipeline Market Report Overview The neurosurgical products pipeline market research report provides comprehensive information about the neurosurgical products pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress. Key Segments ·      Dura Substitutes ·      Neuroendoscopes ·      Neurosurgical Drills ·      Synthetic Dura Substitutes ·      Neurosurgical Drills ·      Biological Dura Substitutes Key Territories ·      The US ·      Europe ·      Canada ·      Israel ·      Japan ·      Philippines...
-
Product Insights
![]()
Alpha Synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha Synuclein Drugs Development Market Report Overview Alpha-synuclein (Non A Beta Component Of AD Amyloid or Non A4 Component Of Amyloid Precursor or NACP or SNCA) is a protein normally found in cells all over the body. It is one of the key players in Parkinson’s. In Parkinson’s it forms clumps inside the specific nerve cells that produce the chemical dopamine. It is involved in the regulation of dopamine release and transport. It induces fibrillization of microtubule-associated protein tau. It...
-
Track & Monitor
![]()
Biosimilars in Pharmaceuticals: Neuro-degenerative receptor binding drug compositions
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Biosimilars in Pharmaceuticals: Peptide-based compositions for Alzheimer’s Disease
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Track & Monitor
![]()
Innovation in Pharmaceuticals: Drugs for neuro-degenerative disorders
Innovation in the pharmaceuticals industry is relentless, making it hard to stay-on top of the dynamically evolving industry landscape and in early identification of profound shifts, posing high risk of being disrupted if detected too late. GlobalData's coherent data-driven approach, using multiple forward-looking alternative datasets, empowers clients by decoding in advance the disruptive innovations in pharmaceuticals industry. Using patents data, GlobalData's proprietary industry innovation s-curve identifies specific innovation areas and their stage of evolution, i.e., whether they are emerging, accelerating...
-
Product Insights
![]()
Alzheimer Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2022 Update
Alzheimer is a progressive neurologic disorder beginning with mild memory loss. It could possibly lead to a loss of the ability to carry on a conversation and respond to the environment. The Alzheimer pipeline market research report provides comprehensive information about the Alzheimer pipeline products with a comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.